BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis.
cellular
combination
drug therapy
immunity
immunotherapy
killer cells
melanoma
natural
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
accepted:
14
07
2020
entrez:
11
9
2020
pubmed:
12
9
2020
medline:
15
10
2021
Statut:
ppublish
Résumé
Targeted therapies and immunotherapies are first-line treatments for patients with advanced melanoma. Serine-threonine protein kinase B-RAF (BRAF) and mitogen-activated protein kinase (MEK) inhibition leads to a 70% response rate in patients with advanced melanoma with a Here we have generated vemurafenib (a BRAF inihibitor)-resistant (R) cells from Vemurafenib resistance involved activation of p-AKT in SK28R and of p-MEK/p-ERK in M14R cells and was accompanied by modulation of NK ligands. Compared with S cells, SK28R displayed an increased expression of natural killer group 2 D (NKG2D) receptor ligands (major histocompatibility complex class (MHC) I chain-related protein A (MICA) and UL16-binding protein 2 (ULBP2)) whereas M14R exhibited decreased ULBP2 . SK28R and M14R cells induced higher NK degranulation and interferon gamma secretion and were more efficiently lysed by donor and patient NK cells. SK28R showed increased tumor necrosis factor-related apoptosis-inducing ligand receptor II (TRAIL-RII) expression and TRAIL-induced apoptosis, and TRAIL-induced apoptosis of M14R was decreased. Combined BRAF/MEK inhibitors abrogated the growth of SK28S, M14S, and M14R cells, while growth of SK28R was maintained. BRAF/MEK inhibition attenuated NK activity but R cell lines activated polyfunctional NK cells and were lysed with high efficiency. We investigated the relationship of soluble NK ligands and response to treatment in a series of melanoma patients. Soluble NKG2D ligands known to regulate the receptor function have been associated to cancer progression. Serum analysis of patients treated with target therapies or IT indicates that soluble forms of NK ligands (MICA, B7H6, programmed cell death ligand 1, and carcinoembryonic antigen cell adhesion molecule 1) may correlate with clinical response. These results support strategies combining targeted therapies and NK-based immunotherapies.
Sections du résumé
BACKGROUND
Targeted therapies and immunotherapies are first-line treatments for patients with advanced melanoma. Serine-threonine protein kinase B-RAF (BRAF) and mitogen-activated protein kinase (MEK) inhibition leads to a 70% response rate in patients with advanced melanoma with a
METHODS
Here we have generated vemurafenib (a BRAF inihibitor)-resistant (R) cells from
RESULTS
Vemurafenib resistance involved activation of p-AKT in SK28R and of p-MEK/p-ERK in M14R cells and was accompanied by modulation of NK ligands. Compared with S cells, SK28R displayed an increased expression of natural killer group 2 D (NKG2D) receptor ligands (major histocompatibility complex class (MHC) I chain-related protein A (MICA) and UL16-binding protein 2 (ULBP2)) whereas M14R exhibited decreased ULBP2 . SK28R and M14R cells induced higher NK degranulation and interferon gamma secretion and were more efficiently lysed by donor and patient NK cells. SK28R showed increased tumor necrosis factor-related apoptosis-inducing ligand receptor II (TRAIL-RII) expression and TRAIL-induced apoptosis, and TRAIL-induced apoptosis of M14R was decreased. Combined BRAF/MEK inhibitors abrogated the growth of SK28S, M14S, and M14R cells, while growth of SK28R was maintained. BRAF/MEK inhibition attenuated NK activity but R cell lines activated polyfunctional NK cells and were lysed with high efficiency. We investigated the relationship of soluble NK ligands and response to treatment in a series of melanoma patients. Soluble NKG2D ligands known to regulate the receptor function have been associated to cancer progression. Serum analysis of patients treated with target therapies or IT indicates that soluble forms of NK ligands (MICA, B7H6, programmed cell death ligand 1, and carcinoembryonic antigen cell adhesion molecule 1) may correlate with clinical response.
CONCLUSION
These results support strategies combining targeted therapies and NK-based immunotherapies.
Identifiants
pubmed: 32912923
pii: jitc-2019-000275
doi: 10.1136/jitc-2019-000275
pmc: PMC7482503
pii:
doi:
Substances chimiques
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Curr Opin Oncol. 2015 Mar;27(2):134-40
pubmed: 25602684
Am J Physiol Lung Cell Mol Physiol. 2006 Aug;291(2):L222-31
pubmed: 16473864
Nat Commun. 2017 Sep 19;8(1):606
pubmed: 28928458
Blood. 2003 Apr 15;101(8):3052-7
pubmed: 12480696
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):718-25
pubmed: 16467081
Oncotarget. 2017 Jun 16;8(43):75675-75686
pubmed: 29088901
Mol Cancer Res. 2008 Jan;6(1):42-52
pubmed: 18234961
J Immunol. 2000 Jul 15;165(2):1153-9
pubmed: 10878395
N Engl J Med. 2010 Aug 26;363(9):809-19
pubmed: 20818844
Clin Cancer Res. 2011 May 1;17(9):2628-37
pubmed: 21224372
EMBO J. 2004 Jan 28;23(2):255-9
pubmed: 14685277
Eur J Cancer. 2016 Mar;55:98-110
pubmed: 26790143
Clin Cancer Res. 2009 Aug 15;15(16):5208-15
pubmed: 19671853
N Engl J Med. 2019 Aug 15;381(7):626-636
pubmed: 31166680
Clin Cancer Res. 2018 Nov 1;24(21):5250-5260
pubmed: 30021908
Neoplasia. 2008 Dec;10(12):1402-10
pubmed: 19048119
Curr Top Microbiol Immunol. 1998;230:41-52
pubmed: 9586349
Oncogene. 2003 May 15;22(19):2869-81
pubmed: 12771938
Immunotherapy. 2011 Feb;3(2):213-27
pubmed: 21322760
Clin Cancer Res. 2013 Feb 1;19(3):598-609
pubmed: 23095323
Nat Immunol. 2016 Aug 19;17(9):1025-36
pubmed: 27540992
Nature. 2012 Jan 26;483(7387):100-3
pubmed: 22281684
Front Immunol. 2018 Sep 11;9:2040
pubmed: 30254634
Cancer Res. 1987 Mar 1;47(5):1411-2
pubmed: 3815344
Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1686-91
pubmed: 18223157
Semin Immunol. 2017 Jun;31:55-63
pubmed: 28943093
N Engl J Med. 2011 Jun 30;364(26):2507-16
pubmed: 21639808
Nat Rev Immunol. 2009 May;9(5):353-63
pubmed: 19365408
Semin Immunol. 2019 Feb;41:101272
pubmed: 31085114
Cancer Immunol Res. 2017 Jul;5(7):582-593
pubmed: 28576831
Hum Pathol. 2011 Dec;42(12):1960-4
pubmed: 21676435
Curr Opin Immunol. 2004 Oct;16(5):626-33
pubmed: 15342010
Cell Signal. 2017 Aug;36:189-203
pubmed: 28495591
Curr Opin Oncol. 2012 Mar;24(2):150-4
pubmed: 22316627
Curr Opin Oncol. 2017 Nov;29(6):484-492
pubmed: 28914644
Cancer Res. 2010 Jul 1;70(13):5213-9
pubmed: 20551059
Cancer Res. 2000 Apr 1;60(7):1800-4
pubmed: 10766161
Crit Rev Immunol. 2016;36(6):445-460
pubmed: 28845754
Cancer. 1999 Jun 1;85(11):2391-9
pubmed: 10357410
J Exp Med. 2000 Apr 17;191(8):1259-62
pubmed: 10770793
Annu Rev Immunol. 1999;17:875-904
pubmed: 10358776
Oncogene. 2008 Oct 6;27(45):5944-58
pubmed: 18836475
Cancer Discov. 2016 Apr;6(4):382-99
pubmed: 26984351
Oncoimmunology. 2017 May 8;6(7):e1323618
pubmed: 28811958
Int J Mol Sci. 2019 Sep 11;20(18):
pubmed: 31514305
Mol Immunol. 2005 Feb;42(4):495-9
pubmed: 15607805
Oncotarget. 2017 Oct 3;8(56):96384-96395
pubmed: 29221214
Nature. 2014 Apr 3;508(7494):118-22
pubmed: 24670642
J Immunother. 2013 Jun;36(5):319-29
pubmed: 23719242
N Engl J Med. 2014 Nov 13;371(20):1877-88
pubmed: 25265492
Expert Opin Biol Ther. 2017 Dec;17(12):1523-1538
pubmed: 28891339